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The Third Birmingham Gynaecological Cancer Workshop: What are we
doing wrong with ovarian cancer?
Held at Queen Elizabeth Hospital, Edgbaston, Birmingham BJ5 2TH, UK.
The outlook for many patients with epithelial ovarian cancer
remains poor despite apparent advances in surgery and
chemotherapy over the past few decades. The Third Birmin-
gham Gynaecological Cancer Workshop was convened to
address specific problems in the management of ovarian
cancer and to determine whether new approaches could be
adopted.
In an attempt to take a different view of ovarian cancer,
speakers from the field presented data which were then
challenged by oncological experts from other fields of cancer,
Professor Giles from the University of Leeds and Dr That-
cher from the Christie Hospital in Manchester. Over the day
discussions were wide ranging but concentrated on several
main issues.
Optimal surgical management
Mr J. Shepherd (St Bartholomew's Hospital and Royal
Marsden Hospital, London) addressed the problem of what
constituted adequate surgery for ovarian cancer. Complete
macroscopic removal of all the tumour if possible was the
primary principle of good surgical management but there was
disagreement about other procedures that should be carried
out. Meticulous staging operations may reveal disease,
especially in the retroperitoneum. There was, however, a
consensus that extensive retroperitoneal dissection was still of
unproven value and was unlikely to make a significant cont-
ribution to the welfare of patients.
Management of stage I and early disease
Mr Shepherd and Professor Pecorelli (Brescia, Italy) present-
ed data on the management of stage I ovarian cancer. In the
London series 80% of patients with genuine stage I disease
have a 5-year survival without any treatment other than
surgical removal. Relapses occur mainly in the first 2-3 years
but it was noted by Dr Wiltshaw (Royal Marsden Hospital,
London) that relapses were occurring even after 8-10 years.
This calls into question the ultimate curability of ovarian
cancer and suggests that its behaviour in the long-term may
be like that of breast cancer, where the data would suggest
that few if any patients can ultimately be said to be cured of
their disease.
Professor Pecorelli then presented data on patients who
had been managed with conservative surgical treatment for
stage I disease. For a variety of reasons, usually the wish to
preserve fertility, only the malignant ovarian cyst had been
removed. Survival in this group of patients was equivalent to
that in populations managed by conventional surgery. In
further studies the 5-year survival of 65 patients with stage
IA grade I tumours who had received no additional therapy
was 100%. Eighty stage IA and IB patients with grade 2/3
tumours were randomised to observation following
laparotomy or six cycles of cisplatinum. There was no
difference in relapse rate (10% in each arm had been
observed so far). One hundred and eight patients with stage
IC disease had been randomised to receive either cisplatinum
or intraperitoneal radiocolloid. Relapse rates of 30% and
26% had been noted. The ultimate impact on survival for
such treatments had not yet been established because of
relatively short follow-up. The role of systemic adjuvant
treatment therefore is still subject to considerable debate.
Salvage therapy may prove to be very effective, especially if
relapse or progression is detected at an early stage, and it
was agreed that the role of adjuvant systemic therapy re-
quired further testing. Trials are in the process of being set
up both in the UK and also on a European basis.
The contribution of surgery in advanced disease was dis-
cussed. The amount of gross tumour removed appears to
influence survival but it was agreed that the ability to debulk
optimally may be associated with intrinsic factors of the
disease rather than surgical technique alone. The role of
surgery in this setting is under re-evaluation at the present
time. Second look laparotomy, that is surgery performed at
the end of primary chemotherapy, has been demonstrated to
have no significant impact on survival in advanced disease.
The role of surgery following two or three courses of
cytoreductive surgery is now being investigated and only
randomised studies will determine the true impact of surgery
in this setting.
Professor Giles reviewed surgical management. He ac-
knowledged that surgical staging per se was unlikely to have
a major influence on survival. He questioned the definition of
adequate local control and pointed out in ovarian cancer that
a reasonable definition of local disease would be disease
within the peritoneum. He urged that all methods of local
extirpation should be considered, with approaches such as
phototherapy and laser destruction being potential means of
controlling disease within the peritoneum. Professor Giles felt
that the interaction between systemic treatment and surgical
intervention required further investigation and such clinical
experiments were urgently needed.
Chemotherapy
The discussion of chemotherapy was introduced by Dr Wilt-
shaw. In a review of patients treated at the Royal Marsden
Hospital over nearly 20 years she demonstrated that the
introduction of cisplatin into treatment protocols had had a
major impact on survival and this had been one major factor
influencing outcome in patients with advanced disease (FIGO
stages III and IV). It remained the case, however, that des-
pite dose intensification and the use of combination therapy,
extension of life with effective chemotherapy remained the
norm and ultimate cure was unlikely in this group of
patients. Further dose intensification using high dose carbo-
platin did appear to be improving the outlook for patients
with stage IV disease in whom the prognosis was particularly
poor, and a randomised trial is underway in earlier stage
disease to see if cures might result.
Toxicity of chemotherapy
The toxicity of drugs such as the platinum compounds
remained a major problem. Neurotoxicity is one of the major
dose limiting effects of cisplatin and can be seen with carbo-
platin, especially when used in combination with cisplatin. Dr
Neijt (Utrecht, Netherlands) reported on the development of
a neuropeptide ORG2766 which appears to protect against
the problems of neurotoxicity. In a randomised study carried
out by the Netherlands Ovarian Cancer Group neurotoxicity
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had been almost completely eliminated when four courses of
cisplatin based chemotherapy were administered concurrently
with this compound and had a major protective effect when
more than four courses were given.
Professor Pecorelli discussed the possibility of dose
intensification using weekly cisplatin therapy. A large pilot
study was currently being carried out by the Northern Italian
Group but randomised trials are required to determine
whether this approach offers potentially significant benefits in
terms of improved response rate, remission duration and
quality of life.
Factors influencing response to chemotherapy and survival
Dr Neijt and Professor Pecorelli both presented analyses of
prognostic factors in patients treated with chemotherapy.
Several factors, including pathological grade, stage of disease
and the radicality of surgery achievable, were of prognostic
significance. There was considerable discussion about how
such prognostic indices might be used prospectively. There
was a concensus that the time was not yet appropriate to
allocate patients to treatment groups on the basis of prognos-
tic indices but that they may provide a useful basis for the
comparison of different studies.
Dr Thatcher commented on the discussions of chemo-
therapy and prognostic factors. He agreed that the necessary
studies of chemotherapy were probably being carried out at
the present time but felt that when assessing prognostic
factors, biochemical parameters such as serum albumin and
possibly tumour markers such as serum CA 125 should be
taken into account. Such factors might prove particularly
important in prognostic indices when groups of patients were
being identified where there was a real decision to be made
about whether treatment should be given or not and what
kind of treatment should be given. Examples of this are
patients with early disease who might be appropriate for
adjuvant therapy or for very poor risk late stage patients
who would be unlikely to benefit from any intensive therapy
at all.
Summary
Stimulating and extensive discussion during the Third Bir-
mingham Workshop showed that clinical researchers are con-
cerned about the limitations of what is being achieved with
ovarian cancer. It is clear, however, that almost all aspects of
therapy are being subjected to close scrutiny. In particular
the question of curability of any ovarian cancer is a major
issue since this will affect the management of both early and
late stage disease and will also determine the sort of trials
which should be carried out for adjuvant treatment. Equally
the role of intensive surgical staging and supraradical surgery
is being questioned at the present time. While chemotherapy
has a palliative role to play, its precise role in tumour
control, achieving a reasonable quality of life for patients
with advanced disease and significantly extending remission
duration are all under investigation. The use of prognostic
indices may help to identify patients who would most benefit
from the various chemotherapy regimens.